Researchers have significantly improved this course of the new treatment for ATTR-CM, utilizing the compound. Early trial information suggests promising improvements for patients diagnosed from a severe disease. This emphasis represents BridgeBio's commitment to managing significant healthcare needs in the heart disease arena. Attruby: BridgeBio's